Decoy Therapeutics Inc. reported on July 27, 2026, that a D-MAV candidate demonstrated in vitro activity against the wild-type Ebola Zaire virus.
This finding validates the D-MAVâ„¢ platform, which was originally engineered to block coronavirus entry.
The company initiated an exploratory program to design D-MAVs against filoviruses, including Ebola and Marburg.
CEO Rick Pierce stated that while respiratory programs remain the priority, this result expands the platform's potential reach.
The successful cross-viral application confirms the technology's ability to target common viral machinery across multiple viruses.